EMBL Logo
Travel and Contact  Staff Only  Site Map  Help?   
Research in Molecular Biology
EMBL Grenoble EMBL Hamburg EMBL heidelberg EMBL-EBI Hinxton EMBL Monterotondo
EMBLAbout UsScience and SocietyEMBL/EMBO Joint Conferences2004Abstracts
General Information
News and Communication
Today at EMBL
Events
Jobs
Alumni Association
Resource Development
Science and Society
EMBL/EMBO
Joint Conferences
2004
Programme
Invited Participants
Abstracts
Symposia
EMBL Forum Lectures
Discussion Meetings
Heidelberg Forum
Publications
PhD Symposium Writing Prize
Related Links
Advanced Training Centre Project
About Us Research Services Education
Image 1 Image 1 Audience
5th EMBL/EMBO Joint Conference 2004 Session II
The foreseeability of real anti-aging medicine

Presentation [PPT]

Unlike most of society, biogerontologists are generally keen to see aging combated as thoroughly as soon as possible. When it comes to translating that view into effective action, however, our record is not impressive. Prominent biogerontologists enjoy exposure in national media that only a tiny minority of other scientists can attract, yet the insatiable public interest in our research has not resulted in comparable public funding. This may largely be due to our reluctance to reconsider a presentational policy that has failed us for 50 years [namely, emphasis on the biomedical pipe-dream termed 'compression of morbidity' and pretence that our work holds no 'risk' of extreme life extension]. Recently we have been committing an even more inexcusable failure, lamentably common in science but no less reprehensible for that: to critique in public, in detail, each other's ideas for combating aging. Only by surviving such scrutiny will any of our proposals achieve enough credibility to attract the funds needed to realise them, so this reticence hurts us all. It prevails for the obvious reasons: successfully challenging one's colleagues' views risks revenge next time they review one's grant application, and doing so unsuccessfully exposes one's own ignorance or carelessness. Silence, by contrast, allows one's views to persist unchallenged indefinitely, which increasingly transforms them from objective opinions into articles of dogmatic faith. Biogerontology is perhaps the field in which this is most reprehensible, given the mind-numbing scale of the deaths for which aging [and, thus, any delay in combating aging] is responsible. Put simply, to place careerist or egoist considerations ahead of our duty to expedite healthy life-extending interventions is an act of self-serving folly that society will not easily forgive when success finally arrives. The greatest absolute life extension hitherto achieved in different species by caloric restriction [CR] or related methods is almost independent of their control lifespan. This fact starkly undermines the currently fashionable extrapolation from rodent CR to predictions of a ~20-year human life extension from foreseeable CR-emulating drugs, and instead predicts a maximum benefit of only 2-3 years – as I have recently argued in depth, in print. My detailed proposal – now four years old – to combat aging not by the 'holistic' approach exemplified by CR, but instead by taking aging apart and repairing each type of cellular or molecular 'damage' independently, has not been reciprocally critiqued, even though several prominent colleagues have publicly endorsed it. I contend that we have an urgent and overwhelming duty to set aside our egos and debate the feasibility of specific approaches to the combating of humanity's foremost remaining scourge
Last updated by: Halldór Stefánsson, 1 August 2007
EMBL Web Support